{
    "clinical_study": {
        "@rank": "43424", 
        "arm_group": [
            {
                "arm_group_label": "Icotinib of routine dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Icotinib: 125mg, oral administration, three times per day."
            }, 
            {
                "arm_group_label": "Icotinib of high dose", 
                "arm_group_type": "Experimental", 
                "description": "Icotinib: 375mg, oral administration, three times per day."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety and efficacy of icotinib at routine dose and\n      higher dose as second-line treatment in non-small cell lung cancer patients with epidermal\n      growth factor receptor of wild type."
        }, 
        "brief_title": "Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients with\n             Histologic or cytologic confirmation.\n\n          -  Wild type epidermal growth factor receptor status.\n\n          -  Progressed after first-line chemotherapy.\n\n          -  No previous systemic anticancer therapy.\n\n          -  Measurable lesion according to response evaluation criteria in solid tumors with at\n             least one measurable lesion not previously irradiated.\n\n          -  Provision of written informed consent.\n\n        Exclusion Criteria:\n\n          -  Evidence of clinically active Interstitial Lung Diseases (Patients with chronic,\n             stable, radiographic changes who are asymptomatic need not be excluded).\n\n          -  Positive epidermal growth factor receptor mutation.\n\n          -  Known severe hypersensitivity to icotinib or any of the excipients of this product.\n\n          -  Evidence of any other significant clinical disorder or laboratory finding that makes\n             it undesirable for the subject to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744925", 
            "org_study_id": "BD-IC-IV26"
        }, 
        "intervention": [
            {
                "arm_group_label": "Icotinib of routine dose", 
                "description": "Icotinib: 125mg, oral administration, three times per day.", 
                "intervention_name": "Icotinib of routine dose", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Conmana", 
                    "BPI-2009"
                ]
            }, 
            {
                "arm_group_label": "Icotinib of high dose", 
                "description": "Icotinib: 375mg, oral administration, three times per day.", 
                "intervention_name": "Icotinib of high dose", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BPI-2009", 
                    "Conmana"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "email": "wangchangli@medmail.com.cn", 
                "last_name": "Changli Wang"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300060"
                }, 
                "name": "Tianjin Medical University Cancer Institute and Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label,Randomized,Controlled Study to Evaluate the Safety and Efficacy for Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR", 
        "overall_contact": {
            "email": "wangchangli@medmail.com.cn", 
            "last_name": "Changli Wang, MD", 
            "phone": "86-022-23340123", 
            "phone_ext": "3031"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University Cancer Institute and Hospital", 
            "last_name": "Changli Wang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, confirmed at least 28 days following the date of the initial response.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744925"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression free survival was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Overall Survival was assessed via calculation of the time to death due to any cause. If a participant was known to have died, the time to death was defined as the time from the date of randomization to the date of death. Otherwise, a participant was censored at the last date they were known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "14 months"
            }, 
            {
                "description": "Adverse events, Serious adverse events , incidence of and reason for study drug dose interruptions and discontinuations, laboratory assessments, vital signs.", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Tianjin Medical University Cancer Institute and Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}